title: Hypofractionated stereotactic radiotherapy with the hypoxic sensitizer AK-2123 (sanazole) for reirradiation of brain metastases: a preliminary feasibility report.
abstract: Reirradiation is a challenging field in the treatment of recurrent brain metastases. Because of the elevated risk of radiation toxicity due to previous irradiation, only a limited dose is prescribed. To enhance radiosensitivity, in the present analysis six patients received hypofractionated stereotactic radiotherapy (hSRT) with daily oral administration of the hypoxic sensitizer AK-2123 (sanazole) for progressive brain metastases after previous radiotherapy. The patients received daily oral administration of 1.0 g/day sanazole up to 2 h before radiotherapy. Three partial and three stable responses were observed, with no sanazole-related toxicity, except for a case of mild nausea. Brain failure with subsequent death occurred in one patient. The other patients maintained good performance status until disease progression in other lesions. hSRT with a hypoxic radiation sensitizer appears to have the potential to enhance the efficacy of radiotherapy.
authors.affiliation: Department of Radiology, Kyoto Prefectural University of Medicine, Kawaramachi Hirokoji, Kyoto, Japan. hideya10@hotmail.com
authors.forename: Hideya
authors.initials: H
authors.lastname: Yamazaki
authors.forename: Satoaki
authors.initials: S
authors.lastname: Nakamura
authors.forename: Takuya
authors.initials: T
authors.lastname: Nishimura
authors.forename: Naohiro
authors.initials: N
authors.lastname: Kodani
authors.forename: Takuji
authors.initials: T
authors.lastname: Tsubokura
authors.forename: Takuya
authors.initials: T
authors.lastname: Kimoto
authors.forename: Hiroya
authors.initials: H
authors.lastname: Sihomi
authors.forename: Norihiro
authors.initials: N
authors.lastname: Aibe
authors.forename: Ken
authors.initials: K
authors.lastname: Yoshida
authors.forename: Masahiko
authors.initials: M
authors.lastname: Koizumi
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Kagiya
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000188:drug therapy / Q000532:radiotherapy* / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D003131:Combined Modality Therapy; D016371:Cranial Irradiation; D019583:Dose Fractionation, Radiation; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage*; D016634:Radiosurgery; D014230:Triazoles / Q000008:administration & dosage*
chemical_list: D011838:Radiation-Sensitizing Agents; D014230:Triazoles; C072690:AK 2123